Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs
Abstract
Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male, presenting a formidable public health problem. Gene therapy has been successfully exploited in several clinical trials. beta-galactosidase(beta-gal) as a reporter gene, has historically been the most popular gene for molecular biology work. A series expression lacZ gene vector was developed and two kinds of prostate cancer cells were screened by histology (X-Galstaining) and beta-gal activity assay method to find highly expressing clones for the lacZ gene. Western blotting confirmed results. It will introduce a novel concept for further exploration for gene therapy using 1beta-galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the prodrugs in vitro and explore growth delay in animal models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2005
- Accession Number
- ADA435644
Entities
People
- Zenyi Ma
Organizations
- University of Texas at Dallas